Cancer Test Co. Overpromised Insurer Coverage, Suit Says
Dermatologic test-maker DermTech Inc. and two of its executives have been hit with an investor's proposed class action alleging they misrepresented their expectations for securing reimbursement coverage broadly from commercial health...To view the full article, register now.
Already a subscriber? Click here to view full article